

**REMARKS**

This paper is submitted in response to the Office Action dated July 28, 2004, the above-identified application.


Applicant thanks the Examiner for the indication that this application is in condition for allowance except for formal matters. The Examiner noted that several amino acid sequences listed in the specification were not assigned SEQ ID NOs. The sequence listing and specification have been amended in accordance with the Examiner's suggestion. In particular, SEQ ID NOs have been assigned to sequences listed in paragraphs 0013, 0017, 0022, and 0031 of the specification. In addition, claim 1 has been amended to correct an inadvertent typographical error. No new matter has been introduced as a result of these amendments to the claims or specification.

Applicants submit herewith a substitute Sequence Listing in computer and paper form, in accordance with 37 C.F.R. §1.821-1.825. The content of the paper and computer-readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same and do not include new matter. A copy of the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and /or Amino Acid Sequence Disclosures, accompanying the Office Communication, is enclosed.

Applicants believe that no fees are due with this timely-filed response. However, should any fees be required in connection with this response, the Commissioner is hereby authorized to charge any required fees to Deposit Account Number 02-4377. A duplicate copy of this page is enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.



Rochelle K. Seide  
Patent Office Reg. No. 32,300

Carmella L. Stephens  
Patent Office Reg. No. 41,328

*Attorneys for Applicants*  
30 Rockefeller Center, 45th floor  
New York, NY 10112

(212) 408-2500

Enclosures